Article Versions Notes

Liu Y, Güler R, Liao Y, Vorobyeva A, Widmark O, Meuleman TJ, Koijen A, van den Bos LJ, Naasz R, Bodenko V, et al. Biologic Evaluation of a Heterodimeric HER2-Albumin Targeted Affibody Molecule Produced by Chemo-Enzymatic Peptide Synthesis. Pharmaceutics. 2022; 14(11):2519. https://doi.org/10.3390/pharmaceutics14112519

Liu, Yongsheng, Rezan Güler, Yunqi Liao, Anzhelika Vorobyeva, Olof Widmark, Theodorus J. Meuleman, Anna Koijen, Leendert J. van den Bos, Robert Naasz, Vitalina Bodenko, and et al. 2022. "Biologic Evaluation of a Heterodimeric HER2-Albumin Targeted Affibody Molecule Produced by Chemo-Enzymatic Peptide Synthesis" Pharmaceutics 14, no. 11: 2519. https://doi.org/10.3390/pharmaceutics14112519

Liu, Y., Güler, R., Liao, Y., Vorobyeva, A., Widmark, O., Meuleman, T. J., Koijen, A., van den Bos, L. J., Naasz, R., Bodenko, V., Orlova, A., Ekblad, C., Tolmachev, V., & Frejd, F. Y. (2022). Biologic Evaluation of a Heterodimeric HER2-Albumin Targeted Affibody Molecule Produced by Chemo-Enzymatic Peptide Synthesis. Pharmaceutics, 14(11), 2519. https://doi.org/10.3390/pharmaceutics14112519